Please login to the form below

Not currently logged in
Email:
Password:

adalimumab-atto

This page shows the latest adalimumab-atto news and features for those working in and with pharma, biotech and healthcare.

New EU and US approvals for Humira biosimilars

New EU and US approvals for Humira biosimilars

Humira (adalimumab) has been the wold's biggest selling drug for years, and made $16bn in sales last year for AbbVie, with a little under $6bn of that total coming from ... It is the second to claim marketing approval in the US market after Amgen's

Latest news

  • Amgen wins European approval for Humira biosimilar Amgevita Amgen wins European approval for Humira biosimilar Amgevita

    Amgevita (biosimilar adalimumab) is both Amgen’s first biosimilar and now the first Humira biosimilar to be approved in Europe. ... Amgen’s Humira biosimilar was approved last September in the US under the brand name Amjevita (adalimumab-atto), whose

  • Amgen claims first US go-ahead for Humira biosimilar Amgen claims first US go-ahead for Humira biosimilar

    brand. The approval is however just the first step in what is likely to be a long journey before the biosimilar - called Amjevita (adalimumab-atto; formerly ABP 501) - can be prescribed ... Meanwhile AbbVie has already filed a lawsuit against Amgen

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

AI and genomics: a revolution in drug discovery and development
...
Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....

Infographics